Naltrexone and Propranolol Combined With Immunotherapy

This study is investigating whether adding two existing drugs — naltrexone (commonly used for addiction) and propranolol (a beta-blocker used for heart conditions) — to standard immunotherapy improves outcomes in people with advanced melanoma (skin cancer). The standard immunotherapy being used is ipilimumab plus nivolumab. Researchers believe these drugs may enhance the immune system's ability to fight cancer. **You may be eligible if...** - You are 18 years or older with advanced melanoma (unresectable stage III or stage IV) - You are a candidate for standard immunotherapy with ipilimumab and nivolumab - You are physically well enough to carry out normal daily activities (ECOG 0–1) - Your liver, kidney, and blood counts are within acceptable ranges - You have a life expectancy of at least 6 months - You have not taken any small-molecule targeted therapies in the past 2 weeks (prior targeted therapy is allowed) **You may NOT be eligible if...** - You have untreated or actively progressing brain metastases - You have a serious autoimmune disease requiring ongoing treatment with steroids or immune-suppressing drugs - You are pregnant or breastfeeding - You are already enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.